This trial will evaluate the safety, pharmacokinetics, and efficacy of ivermectin in scabies
infected children weighing 5 to less than 15kg. This will allow future efforts to expand the
indication of ivermectin treatment to infants weighing 5 to less than 15kg to treat numerous
NTDs, allowing this young age group equitable access to the numerous benefits of ivermectin
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
Chittagong Medical College Kenya Medical Research Institute Manhiça Health Research Centre (CISM) The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD)